Leuven, Belgium-based icometrix has secured $18 million in funding from Forestay Capital, Optum Ventures and prior backer Capricorn Venture Partners.

The company claims its technology has the potential to transform care for patients with brain injuries and disorders, by extracting clinically meaningful information from brain MRI and CT scans of patients.

Its ‘icobrain’ software platform is both CE-marked and FDA-cleared, the company notes, and already in use by more than 100 hospitals and imaging center networks worldwide, as well as in clinical studies by 4 out of the top 5 pharma companies.

“One in three people will suffer from a brain disorder, often due to a chronic disease, leading to an immense burden for patients, friends, families, caregivers and society. Brain scans play a central role in patient diagnosis and monitoring, creating a huge need for objective and patient-specific evaluation of MRI and CT brain scan images with tools like icobrain,” explains Wim Van Hecke, CEO of icometrix.

“We strongly believe in the power of data to help diagnose, monitor and treat neurological disorders,” said Heather Roxborough, Partner at Optum Ventures. “By putting icometrix’s innovative AI brain imaging solutions in the hands of clinicians and radiologists worldwide, we can help improve the lives of millions of people with brain disorders.”

ICYMI: Throughout May, Tech.eu is focused on surfacing interesting stories, startups and people from the health/medtech industry, powered by Bayer G4A. With this program, the health industry giant aims to establish long-term partnerships with interesting digital health startups.

Comments are closed.